(IN BRIEF) Boehringer Ingelheim has launched SCOVELLA® (velagliflozin oral solution) in Great Britain, the first therapy specifically developed and approved to treat hyperinsulinemia in insulin-dysregulated horses and ponies that do not respond sufficiently to husbandry and exercise changes. Insulin dysregulation … Read the full press release →
Posted in Agriculture, Business, Germany, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged 38% untreated controls, Animal Health, April 2026, BEVA Congress, Boehringer Ingelheim, Boehringer Ingelheim Introduces SCOVELLA® for Horses and Ponies at Risk of Laminitis, Bracknell, British Equine Veterinary Association, circulating insulin, clinical research, Craig Beck, dietary challenge trial, equine health, equine laminitis, equine medicine, equine veterinarians, exercise regimen, Germany, Great Britain, horse health, horse welfare, horses, husbandry, hyperinsulinemia, ID, Ingelheim, insulin concentrations, insulin dysregulation, laminitis, limited marketing authorisation, Liphook Equine Hospital, oral liquid therapy, ponies, Professor Andy Durham, Saskia Kley, SCOVELLA, SCOVELLA® Becomes First Licensed Therapy for Equine Insulin Dysregulation in Great Britain, SCOVELLA® Targets Hyperinsulinemia in Insulin-Dysregulated Horses and Ponies, September 2026, SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor, UK Veterinary Medicines Regulations, United Kingdom, velagliflozin, velagliflozin oral solution, veterinary innovation, veterinary medicine, Veterinary Medicines Directorate, veterinary surgeons, VMD
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
Load more...
